FINWIRES · TerminalLIVE
FINWIRES

Chardan Initiates Camp4 Therapeutics at Buy With $6.50 Price Target

By

Camp4 Therapeutics (CAMP) has an average rating of buy and mean price target of $7.79, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

Barclays Downgrades Nuvalent to Equalweight From Overweight, $124 Price Target

Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $123.08, Change: $+34.59, Percent Change: +39.08%

$NUVL
Research

Raymond James Downgrades Nuvalent to Market Perform From Outperform

Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $122.87, Change: $+34.38, Percent Change: +38.85%

$NUVL
Research

Wells Fargo Downgrades Nuvalent to Equalweight From Overweight, Adjusts Price Target to $124 From $116

Nuvalent (NUVL) has an average rating of overweight and mean price target of $141.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$NUVL